BEAM / Beam Therapeutics Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 BEAM THERAPEUTICS INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optima

Exhibit 99.1 Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-c

Article I DEFINITIONS AND INTERPRETATION Article II LOANS Article III CONDITIONS PRECEDENT Article IV REPRESENTATIONS AND WARRANTIES Article V AFFIRMATIVE COVENANTS Article VI NEGATIVE COVENANTS Article VII GUARANTY Article VIII EVENTS OF DEFAULT Art

Exhibit 10.1 Certain information, marked by [***], has been excluded from this exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. FINANCING AGREEMENT dated as of February 24, 2026 among BEAM THERAPEUTICS INC., as Borrower, CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, VARIOUS LENDERS FROM TIME TO TIME PARTY HERE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

ARS

Dear Fellow Shareholders, At Beam, our vision is to provide lifelong cures for patients suffering from serious diseases.

FORM 8-K Item 1.02 Termination of a Material Definitive Agreement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 02, 2026 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 BEAM THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing

Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti

Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par value per sha

As filed with the Securities and Exchange Commission on February 24, 2026

As filed with the Securities and Exchange Commission on February 24, 2026 Registration No.

FORM 8-K Item 1.01 Entry into a Material Definitive Agreement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 09, 2026 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissio

STANDBY LICENSE AGREEMENT BEAM THERAPEUTICS INC. BIO PALETTE CO., LTD. NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY Exhibit A Prime License [***] Exhibit B License Agreement [***] Exhibit C Kobe P

CERTAIN IMMATERIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(a)(5), (a)(6) and (b)(10)(iv).

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2026 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Alignment Reached with U.S. FDA on Potenti

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Alignment Reached with U.

The Power of Predictability JANUARY 2026 NASDAQ: BEAM

The Power of Predictability JANUARY 2026 NASDAQ: BEAM Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

FORM 8-K Item 2.01 Completion of Acquisition or Disposition of Assets.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clini

Exhibit 99.1 Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease Accepted for Pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 BEAM THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

144

144 0001786304 XXXXXXXX LIVE 0001745999 BEAM THERAPEUTICS INC. 001-39208 238 Main Street Cambridge MA 02142 (857) 327-8775 JOHN M EVANS Officer Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 25000 615667.50 100557094 10/02/2025 NASDAQ Common 10/02/2025 Stock Option Exercise ISSUER N 25000 10/02/2025 Cash N JOHN M EVANS 238

144

144 0001786304 XXXXXXXX LIVE 0001745999 BEAM THERAPEUTICS INC. 001-39208 238 Main Street Cambridge MA 02142 (857) 327-8775 JOHN M EVANS Officer Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 25000 612655.00 101162026 10/01/2025 NASDAQ Common 10/01/2025 Stock Option Exercise ISSUER N 25000 10/01/2025 Cash Y 10/01/2025 05/16/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap

Amended and Restated Non-Employee Director Compensation Policy, dated June 2, 2025.

Exhibit 10.1 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of June 2, 2025) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the following

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 BEAM THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Cor

Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded Dose Explor

FORM 8-K Item 3.02 Unregistered Sales of Equity Securities.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi

FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 04, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of incor

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Dat

Exhibit 99.1 Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

ARS

Dear Fellow Shareholders, At Beam, our vision is to develop lifelong cures for patients suffering from serious diseases.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Beam Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission F

Beam Therapeutics Announces Pricing of Underwritten Offering

Exhibit 99.1 Beam Therapeutics Announces Pricing of Underwritten Offering Cambridge, Mass., March 10, 2025 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock

Joint bookrunning managers J.P. Morgan  Jefferies  Cantor  Citigroup  Wells Fargo Securities

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-277427 The information in this preliminary prospectus supplement is not complete and may be changed. The registration statement filed with the Securities and Exchange Commission relating to these securities is effective. This preliminary prospectus supplement is not an offer to sell these securities and we are not solicitin

Form of Pre-funded Warrant

Exhibit 4.1 BEAM THERAPEUTICS INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: [], 2025 Beam Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its permitted registered assign

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission F

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation Single Dose of BEAM-302 Led to Durable,

Exhibit 99.1 Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Beam Therapeutics Inc.

BEAM THERAPEUTICS INC. Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock

FWP 1 d926256dfwp.htm FWP Issuer Free Writing Prospectus dated March 10, 2025 Filed Pursuant to Rule 433 Registration No. 333-277427 BEAM THERAPEUTICS INC. Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock This free writing prospectus relates only to the offering by Beam Therapeutics Inc. of shares of common stock and, in lieu of shares of common stock for certain inves

Joint bookrunning managers J.P. Morgan  Jefferies  Cantor  Citigroup  Wells Fargo Securities

As Filed Pursuant to Rule 424(b)(5) Registration No. 333-277427 Prospectus supplement (To prospectus dated February 28, 2024) 16,151,686 shares of common stock Pre-funded warrants to purchase 1,404,988 shares of common stock This is an offering of 16,151,686 shares of the common stock of Beam Therapeutics Inc. and, in lieu of common stock for certain investors that so choose, pre-funded warrants t

Underwriting Agreement, dated March 10, 2025, by and among Beam Therapeutics Inc., J.P. Morgan Securities LLC, Jefferies LLC, Cantor Fitzgerald & Co., Citigroup Global Markets Inc. and Wells Fargo Securities, LLC

Exhibit 1.1 Beam Therapeutics Inc. 16,151,686 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,404,988 Shares of Common Stock Underwriting Agreement March 10, 2025 J.P. Morgan Securities LLC Jefferies LLC Cantor Fitzgerald & Co. Citigroup Global Markets Inc. Wells Fargo Securities, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par

Amendment No. 4 to License Agreement, between the President and Fellows of Harvard College and Beam Therapeutics Inc., dated December 1, 2024

Exhibit 10.42 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. AMENDMENT NO. 4 TO LICENSE AGREEMENT This Amendment (“Amendment No. 4”), effective as of December 11, 2024 (“Amendment No. 4 Effective Date”), is entered into by and between Be

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

As filed with the Securities and Exchange Commission on February 25, 2025

As filed with the Securities and Exchange Commission on February 25, 2025 Registration No.

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Ex

Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Exp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti

Letter Agreement between Beam Therapeutics Inc. and Sravan K. Emany, dated December 2, 2024

Exhibit 10.18 November 25, 2024 Mr. Sravan K. Emany 811 Cedar Terrace Westfield N.J. 07090 Re: Offer of Employment Dear Sravan, Beam Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Start Date. Provided that you satisfy the conditions described at the end of this letter agreement (this “Agreement”), your first day of employment with the Company will

Insider Trading Policy

Exhibit 19.1 Beam Therapeutics Inc. Insider Trading Policy (as amended and restated as of December 5, 2024) 1. Purpose. This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of, and handling confidential information about, Beam Therapeutics Inc. (the “Company”) and Applicable Other Companies (as defined below). The Company’s Board of Directo

AGREEMENT

EX-1 2 exh118926.htm AGREEMENT Exhibit 1 AGREEMENT Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Beam Therapeutics, Inc. This Agreement may be executed in any number of counte

EX-99

EX-99 2 exhibit99.txt Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A FIAM LLC IA Fidelity Institutional Asset Management Trust Compan

JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k)

EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients a

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing

PRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025

PRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%

Exhibit 99.1 Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety Profile Consistent with Busulfan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2024 Beam Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting NHP D

Exhibit 99.2 Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Beam Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Exhibit 99.1 Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer Cambridge, Mass., December 6, 2024 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a br

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Beam Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Exhibit 99.1 Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader Cambridge, Mass., December 4, 2024 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at M

BEAM / Beam Therapeutics Inc. / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.6 BEAM THERAPEUTICS INC COMMON STOCK Cusip #07373V105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #07373V105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,397,372 Item 6: 0 Item 7: 6,401,146 Item 8: 0 Item 9: 6,401,146 Item 11:

BEAM / Beam Therapeutics Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us07373v1052110824.txt us07373v1052110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) Beam Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 07373V105 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriat

BEAM / Beam Therapeutics Inc. / Farallon Capital Partners, L.P. Passive Investment

SC 13G/A 1 beam13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (Cusip Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriat

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH

Exhibit 99.1 Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T

Q3 Financial Results & ASH Abstracts Investor Webcast November 5, 2024

Q3 Financial Results & ASH Abstracts Investor Webcast November 5, 2024 Beam conference call participants Beam’s Sickle Cell Disease Strategy Q3 Business Update Introduction ASH Abstract: ESCAPE Preclinical Data ASH Abstracts: BEAM-101 Clinical Data Mr.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissio

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting Initial Results from BEACON Pha

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting Initial Results from BEACON Phase 1/2 Clinical Trial Demonstrate Potential for Differentiation of Base Editing and BEAM-101 Preclinical ESCAPE Data Establish Proof-of-concept for Non-genotoxic, Antibody-based Conditioning and Engraftment in Non-human Primates Clinical Data from Phase 1/2 BEAM-201 Trial Demonstrate Therapeutic Potential of First Quadruplex-edited Allogeneic CAR-T Cell Therapy Beam to Host Investor Event on Dec.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

BEAM / Beam Therapeutics Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us07373v1052102124.txt us07373v1052102124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) Beam Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 07373V105 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriat

BEAM / Beam Therapeutics Inc. / STATE STREET CORP Passive Investment

SC 13G/A 1 BeamTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BEAM THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 07373V105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 BEAM THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap

Amendment to License Agreement between The Broad Institute, Inc. and Beam Therapeutics Inc., dated May 31, 2024

Exhibit 10.3 Third Amendment to License Agreement This Third Amendment (“Amendment”), effective as of May 31, 2024 (“Amendment Effective Date”), is entered into by and between Beam Therapeutics Inc., as a successor in interest to Blink Therapeutics Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 238 Main Street, 9th Floor, Cambridge, Massachusett

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients E

Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease Initial Clinical Data for BEAM-101 and

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi

Beam Therapeutics Announces Transition of Chief Financial Officer

Exhibit 99.1 Beam Therapeutics Announces Transition of Chief Financial Officer Cambridge, Mass., July 15, 2024 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chair

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA

Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 BEAM THERAPEUTICS INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of incor

Form of Addendum to Letter Agreement between Beam Therapeutics Inc. and each of its executive officers

Exhibit 10.2 [-] RE: Addendum to Executive Letter Agreement Dear [-], This letter serves as an addendum to your Executive Letter Agreement, dated [-]. See Appendix A for details around the revisions to your severance provisions. All other terms and conditions of your original letter of offer remain the same. Sincerely, [-] Beam Therapeutics, Inc. Acceptance: I understand and accept the conditions

Amended and Restated Beam Therapeutics Inc. Non-Employee Director Compensation Policy

Exhibit 10.1 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of April 1, 2024) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the followin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

ARS

Dear Fellow Shareholders, Beam was built from the beginning to push the gene editing field forward.

Form of Subordinated Note

EX-4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N

As filed with the Securities and Exchange Commission on February 27, 2024

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 27, 2024 Registration No.

Form of Senior Indenture

EX-4.3 Exhibit 4.3 BEAM THERAPEUTICS INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b)

Form of Subordinated Indenture

EX-4.4 Exhibit 4.4 BEAM THERAPEUTICS INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.086.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.014.04 312(b) 4.04 (c) 312(c) 4.04 (c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02

Form of Senior Note

EX-4.5 Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Sales Agreement, dated as of April 1, 2021, as subsequently amended on July 7, 2021 and May 10, 2023, by and between the Registrant and Jefferies, LLC

EX-1.2 Exhibit 1.2 BEAM THERAPEUTICS INC. SALES AGREEMENT April 1, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Beam Therapeutics Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Com

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beam Therapeutics Inc.

As filed with the Securities and Exchange Commission on February 27, 2024

As filed with the Securities and Exchange Commission on February 27, 2024 Registration No.

Third Amendment to Lease, between Beam Therapeutics Inc. and ARE-NC Region No.14, LLC, dated January 1, 2024

Exhibit 10.41 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (this “Third Amendment”) is made as of January 1st, 2024 (“Effective Date”), by and between ARE-NC REGION NO. 14, LLC, a Delaware limited liability company (“Landlord”), and BEAM THERAPEUTICS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 11,

Amended and Restated Beam Therapeutics Inc. Non-Employee Director Compensation Policy, dated January 22, 2024

Exhibit 10.29 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of January 22, 2024) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the foll

First Amendment to Lease, between Beam Therapeutics Inc. and ARE-NC Region No. 14, LLC, dated June 23, 2022

Exhibit 10.39 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this “First Amendment”) is made as of June 23, 2022, by and between ARE-NC REGION NO. 14, LLC, a Delaware limited liability company (“Landlord”), and BEAM THERAPEUTICS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 11, 2020 (the “Lease”), wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 BEAM THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical

Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation for BEAM-302 in Alpha-1 Antitrypsin Deficiency on Track for First Half o

Clawback Policy

Exhibit 97.1 BEAM THERAPEUTICS INC. Clawback Policy This Clawback Policy (this “Policy”), adopted by Beam Therapeutics Inc. (the “Company”), relates to the Company’s right to recover compensation previously paid to specified employees in certain circumstances, including the recovery of Erroneously Awarded Compensation (as defined below) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), wh

Second Amendment to Lease, between Beam Therapeutics Inc. and ARE-NC Region No. 14, LLC, dated March 31, 2023

Exhibit 10.40 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Second Amendment”) is made as of March 31, 2023, by and between ARE-NC REGION NO. 14, LLC, a Delaware limited liability company (“Landlord”), and BEAM THERAPEUTICS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 11, 2020, as amended b

Filing Fee Table

Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par value per sha

BEAM / Beam Therapeutics Inc. / ARCH Venture Fund IX, L.P. - ARCH VENTURE FUND IX, L.P. - BEAM THERAPEUTICS -- SCH 13G/A(#2) Passive Investment

SC 13G/A 1 arch-sch13g18793.htm ARCH VENTURE FUND IX, L.P. - BEAM THERAPEUTICS - SCH 13G/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Beam Therapeutics, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2023 (Date

BEAM / Beam Therapeutics Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Beam Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 07373V105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

BEAM / Beam Therapeutics Inc. / Farallon Capital Partners, L.P. Passive Investment

SC 13G/A 1 beam13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate

BEAM / Beam Therapeutics Inc. / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 BEAM THERAPEUTICS INC COMMON STOCK Cusip #07373V105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #07373V105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,950,571 Item 6: 0 Item 7: 8,953,800 Item 8: 0 Item

BEAM / Beam Therapeutics Inc. / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Secur

BEAM / Beam Therapeutics Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm244117d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Beam Therapeutics Inc. (Name of Issuer) Common stock (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de

BEAM / Beam Therapeutics Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us07373v1052012524.txt us07373v1052012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Beam Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 07373V105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate

BEAM / Beam Therapeutics Inc. / STATE STREET CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING BEAM THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 07373V105 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS

PRECISION GENETIC MEDICINES THROUGH BASE EDITING JANUARY 2024 NASDAQ: BEAM

PRECISION GENETIC MEDICINES THROUGH BASE EDITING JANUARY 2024 NASDAQ: BEAM Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024 European Clinical Trial Application (CTA) Submitted for BEAM-302; Trial Initiation in Alpha-1 Antitrypsin Deficiency Planned for First Half of 2024 Investigational New Drug (IND) Application for BEAM-301 On-track for First Half of 2024 Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass.

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

EX-99.1 Exhibit 99.1 Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors CAMBRIDGE, Mass., Dec. 14, 2023 - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquir

Exhibit 99.1 Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, E

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 CAMBRIDGE, Mass.

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinica

EX-99.1 PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinical studies and research and development programs,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 BEAM THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Highest priority programs – BEAM-101 and ESCAPE for sickle cell

EX-99.2 Exhibit 99.2 Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company t

LETTER

United States securities and exchange commission logo October 12, 2023 Terry-Ann Burrell Chief Financial Officer and Treasurer Beam Therapeutics Inc.

BEAM / Beam Therapeutics Inc / Farallon Capital Partners, L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Rule 83 Confidential Treatment Request by Beam Therapeutics Inc. Request #1

CONFIDENTIAL TREATMENT REQUEST UNDER RULE 83 The entity requesting confidential treatment is: Beam Therapeutics Inc.

LETTER

United States securities and exchange commission logo August 22, 2023 Terry-Ann Burrell Chief Financial Officer and Treasurer Beam Therapeutics Inc.

*****

August 9, 2023 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Mary Mast and Ms. Angela Connell Re: Beam Therapeutics Inc. Form 10-K for the Year Ended December 31, 2022 Filed February 28, 2023 File No. 001-39208 Dear Ms. Mast and Ms. Connell: Beam Therapeutics Inc. (“Beam”) prov

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient

Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of BEAM-201 in T-ALL/T-LL and Expected to be Dosed in The Third Quarter of 2023 Company to Accelerate Develo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 BEAM THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap

LETTER

United States securities and exchange commission logo July 20, 2023 Terry-Ann Burrell Chief Financial Officer and Treasurer Beam Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2023 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi

Up to $300,000,000 BEAM THERAPEUTICS INC. Common Stock

424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254946 PROSPECTUS SUPPLEMENT (To Prospectus dated April 1, 2021) Up to $300,000,000 BEAM THERAPEUTICS INC. Common Stock We have entered into an amendment, dated May 10, 2023, or Amendment No. 2, to the Sales Agreement with Jefferies LLC, or the sales agent, dated April 1, 2021, or the sales agreement, as previously am

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on

Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites Activated and Additional Patients Enrolled in BEACON Clinical Trial of BEAM-101 for Patients with Sickle Cel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera

Amendment No. 2 to Sales Agreement, dated May 10, 2023, by and between Beam Therapeutics Inc. and Jefferies LLC

Exhibit 1.1 AMENDMENT NO. 2 TO THE SALES AGREEMENT May 10, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 2 to the sales agreement (this “Amendment No. 2”) is entered into as of the date first written above by Beam Therapeutics Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), that are parties to that certain sal

Letter Agreement between Beam Therapeutics Inc. and Christine Bellon, dated January 24, 2020

January 24, 2020 Dear Christine, This letter agreement (this "Agreement") confirms the terms and conditions of your employment with Beam Therapeutics Inc.

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Beam Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Ca

EX-FILING FEES 2 d465744dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Beam Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maxim

Amended and Restated Beam Therapeutics Inc. Non-Employee Director Compensation Policy.

Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of March 31, 2023) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the following amounts of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BEAM THERAPEUTICS IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco

Letter Agreement between Beam Therapeutics Inc. and Amy Simon, dated January 29, 2021

January 29, 2021 Amy R. Simon, M.D. 18 Hammond Street Chestnut Hill, MA 02467 Dear Amy, This letter agreement (this “Agreement”) confirms the terms and conditions of your employment with Beam Therapeutics Inc. (the “Company”), effective as of March 22, 2021 (the “Effective Date”). 1. Position. Your position with the Company will be Chief Medical Officer. You agree to perform the duties of your pos

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BEAM THERAPEUTICS IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BEAM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

ARS

Dear Fellow Shareholders, As I think back on the past year, I can’t help but reflect with amazement on the progress that the field of gene editing has made in the last decade.

BEAM / Beam Therapeutics Inc / Temasek Holdings (Private) Ltd - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portf

Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base Editing Medicines North Carolina Manufacturing Facility Open and Operatio

Amendment No. 4 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated December 7, 2022

FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (this “Fourth Amendment”) is made as of December 7, 2022 by and between MIT 238 MAIN STREET LEASEHOLD LLC, a Massachusetts charitable corporation with an address c/o MIT Cambridge Real Estate LLC, One Broadway, Suite 09-200, Cambridge, MA 02142 (“Landlord”), and BEAM THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 BEAM THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

Second Amended and Restated Bylaws of Beam Therapeutics Inc.

BEAM THERAPEUTICS INC. SECOND AMENDED AND RESTATED BYLAWS SECTION 1 — STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders of Beam Therapeutics Inc., a Delaware corporation (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the place

Filing Fee Table

Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par value per sha

As filed with the Securities and Exchange Commission on February 28, 2023

As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti

BEAM / Beam Therapeutics Inc / Farallon Capital Partners, L.P. Passive Investment

SC 13G/A 1 13ga1beam.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (Cusip Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriat

BEAM / Beam Therapeutics Inc / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

BEAM / Beam Therapeutics Inc / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment

SC 13G/A 1 d461102dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per

BEAM / Beam Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Beam Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 07373V105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

BEAM / Beam Therapeutics Inc / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.4 BEAM THERAPEUTICS INC COMMON STOCK Cusip #07373V105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #07373V105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,767,498 Item 6: 0 Item 7: 7,769,016 Item 8: 0 Item 9: 7,769,016 Item 11:

BEAM / Beam Therapeutics Inc / BlackRock Inc. Passive Investment

SC 13G/A 1 us07373v1052020223.txt us07373v1052020223.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) BEAM THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 07373V105 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinica

EX-99.1 PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinical studies and research and development programs,

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in

EX-99.2 Exhibit 99.2 Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BEAM THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BEAM THERAPEUTICS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 BEAM THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling S

Exhibit 99.1 Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Defi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 02, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 on Track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Cli

Exhibit 99.1 Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 on Track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022 John Lo, Ph.D., Appointed as Chief

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application

EX-99.1 2 beam-ex991.htm EX-99.1 Exhibit 99.1 Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application CAMBRIDGE, Mass., August 1, 2022 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that on Friday, July 29, 2022, the company was informed via e-mail communication from the U.S. Food and D

BEAM / Beam Therapeutics Inc / Farallon Capital Partners, L.P. - INITIAL 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Na

Exhibit 99.1 Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiated in People with Sickle Trait to Provide Insights into Key Characteristics of Sickle Cell Trait and Sickle Ce

Amended and Restated Non-employee Director Compensation Policy

Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of March 31, 2022) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the ?Company?) as a director, other than a director who is employed by the Company or a subsidiary (a ?Non-Employee Director?), shall be entitled to receive the following amounts of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 beam2022noticeandpro.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 beam2022proxymaterial.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b

Amendment No. 2 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated November 17, 2020

Exhibit 10.32 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this ?Second Amendment?) is made as of November 17, 2020 by and between MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a Massachusetts charitable corporation with an address of c/o MIT Investment Management Company, One Broadway, Suite 09-200, Cambridge, MA 02142 (?Landlord?), and BEAM THERAPEUTICS, INC., a Delaware corporation with a

Amendment No. 3 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated August 24, 2021

Exhibit 10.33 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (this "Third Amendment") is made as of August 24th 2021 by and between MIT 238 MAIN STREET LEASEHOLD LLC, a Massachusetts charitable corporation with an address of c/o MIT Cambridge Real Estate LLC, One Broadway, Suite 09-200, Cambridge, MA 02142 ("Landlord"), successor-in-interest to Massachusetts Institute of Technology, and BE

Amendment No. 1 to Indenture of Lease, between Massachusetts Institute of Technology and Beam Therapeutics Inc., dated April 14, 2020

Exhibit 10.31 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this ?First Amendment?) is made as of April 14th, 2020 by and between MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a Massachusetts charitable corporation with an address of c/o MIT Investment Management Company, One Broadway, Suite 09-200, Cambridge, MA 02142 Landlord?) and BEAM THERAPEUTICS, INC., a Delaware corporation with an addre

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 pa

Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan (previously filed as Exhibit 10.27 to the annual report on Form 10-K filed on February 28, 2022 (File No. 001-39208) and incorporated herein by reference).

Exhibit 10.27 Beam Therapeutics Inc. AMENDED AND RESTATED 2019 Employee Stock Purchase Plan 1. Defined Terms Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. Purpose of Plan The Plan is intended to enable Eligible Employees to use payroll deductions to purchase shares of Stock in offerings under th

List of Subsidiaries of Beam Therapeutics Inc.

Exhibit 21.1 Subsidiaries of Beam Therapeutics Inc. Entity State or other Jurisdiction of Incorporation or Organization Beam Therapeutics Securities Corporation Massachusetts Guide Therapeutics, LLC Delaware

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

As filed with the Securities and Exchange Commission on February 28, 2022

S-8 1 d313692ds8.htm S-8 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 81-5238376 (State or other jurisdiction of incorporatio

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Bill

Exhibit 99.1 Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of Long-term Strategy for Sickle Cell Disease with Planned Initiation of BEAM-101 Clinical Trial and IND Submiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti

BEAM / Beam Therapeutics Inc / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Secur

BEAM / Beam Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) BEAM THERAPEUTICS Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

BEAM / Beam Therapeutics Inc / ARCH Venture Fund IX, L.P. - ARCH VENTURE FUND IX, L.P. - BEAM THERAPEUTICS -- SCH 13G/A(#1) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Beam Therapeutics, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r

BEAM / Beam Therapeutics Inc / HILLHOUSE CAPITAL ADVISORS, LTD. - BEAM THERAPEUTICS INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.01 par value per share, of Beam Therapeutics Inc.,

BEAM / Beam Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Beam Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 07373V105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??

BEAM / Beam Therapeutics Inc / FMR LLC Passive Investment

SCHEDULE 13G Amendment No. 2 BEAM THERAPEUTICS INC COMMON STOCK Cusip #07373V105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #07373V105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,989,617 Item 6: 0 Item 7: 5,989,698 Item 8: 0 Item 9: 5,989,698 Item 11:

BEAM / Beam Therapeutics Inc / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

BEAM / Beam Therapeutics Inc / BlackRock Inc. Passive Investment

us07373v1052020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) BEAM THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 07373V105 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

BEAM / Beam Therapeutics Inc / FMR LLC Passive Investment

SCHEDULE 13G Amendment No. 3 BEAM THERAPEUTICS INC COMMON STOCK Cusip #07373V105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #07373V105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,989,617 Item 6: 0 Item 7: 6,818,422 Item 8: 0 Item 9: 6,818,422 Item 11:

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle

Exhibit 99.2 Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Typ

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinica

PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T

Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway

Exhibit 99.1 Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 8, 2021 -Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing,

Amended and Restated Letter Agreement between Beam Therapeutics Inc. and John Evans dated June 9, 2021

Exhibit 10.1 June 9, 2021 John Evans Dear John: This amended and restated letter agreement (this ?Agreement?) confirms the terms and conditions of your employment as the Chief Executive Officer of Beam Therapeutics Inc. (the ?Company?), working out of the Company?s headquarters located in Cambridge, Massachusetts, effective as of June 9, 2021 (the ?Effective Date?). 1. Position and Duties. a. Effe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of i

Amended and Restated Beam Therapeutics Inc. Non-Employee Director Compensation Policy dated June 10, 2021.

Exhibit 10.2 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of June 10, 2021) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the ?Company?) as a director, other than a director who is employed by the Company or a subsidiary(a ?Non-Employee Director?), shall be entitled to receive the following

Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initia

Exhibit 99.1 Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE, Mass., Aug. 10, 2021 -Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.01 par value per share $500,000,000.00 $54,550.00

Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254946 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.01 par value per share $500,000,000.00 $54,550.00 (1) The securities registered herein are offered pursuant to an automatic shelf registration

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 BEAM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission Fil

Amendment No. 1 to Sales Agreement, dated July 7, 2021, by and between Beam Therapeutics Inc. and Jefferies LLC

Exhibit 1.1 AMENDMENT NO. 1 TO THE SALES AGREEMENT July 7, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement (this ?Amendment?) is entered into as of the date first written above by Beam Therapeutics Inc., a Delaware corporation (the ?Company?), and Jefferies LLC (the ?Agent?), that are parties to that certain Sales Agr

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco

BEAM / Beam Therapeutics Inc / ARK Investment Management LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

As filed with the Securities and Exchange Commission on June 10, 2021

Table of Contents As filed with the Securities and Exchange Commission on June 10, 2021 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco

Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results Data from Beam’s Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52% Company On-track to Subm

Exhibit 99.1 Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results Data from Beam’s Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52% Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 CAMBRIDGE, Mass., May 11, 2021 - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnol

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

SC 13G/A

us07373v1052040921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) BEAM THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 07373V105 - (CUSIP Number) March 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee(3) Common Stock, $0.01 par value per share $79,885,248.30 $8,715.49

424B7 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee(3) Common Stock, $0.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 1, 2021 Date of Report (Date of earliest event reported) BEAM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission Fil

Form of Indenture

Exhibit 4.5 BEAM THERAPEUTICS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establish

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee(3) Common Stock, $0.01 par value per share $205,292,750.00 $22,397.44

424B7 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee(3) Common Stock, $0.

Form S-3

Table of Contents As filed with the Securities and Exchange Commission on April 1, 2021 Registration No.

Exhibit 4.11

Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes all material provisions of the common stock, par value $0.01 per share, of Beam Therapeutics Inc. The description of our common stock and certain provisions of our amended and restated certificate of incorporation, or our certificate of in

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.01 par value per share $300,000,000 $32,730.00

424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.

Sales Agreement, dated April 1, 2021, by and between Beam Therapeutics Inc. and Jefferies LLC.

Exhibit 1.1 BEAM THERAPEUTICS INC. SALES AGREEMENT April 1, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Beam Therapeutics Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s

- S-8

As filed with the Securities and Exchange Commission on March 17, 2021 Registration No.

Form of Restricted Stock Award Agreement under the Beam Therapeutics Inc. 2019 Equity Incentive Plan

Exhibit 10.26 Beam Therapeutics Inc. 2019 Equity Incentive Plan Restricted Stock Award Agreement This agreement (this ?Agreement?), is made effective as of [ ], 2020 (the ?Date of Grant?), by and between Beam Therapeutics Inc. (the ?Company?) and [] (the ?Participant?). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Beam Therapeutics Inc. 2019

List of Subsidiaries of Beam Therapeutics Inc.

Exhibit 21.1 Subsidiaries of Beam Therapeutics, Inc. Entity State or other Jurisdiction of Incorporation or Organization Blink Therapeutics, Inc. Delaware Beam Therapeutics Securities Corporation Massachusetts Guide Therapeutics, LLC Delaware

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti

Form of Restricted Stock Unit Award Agreement under the Beam Therapeutics Inc. 2019 Equity Incentive Plan

Exhibit 10.25 Name: Number of Restricted Stock Units subject to Award: Date of Grant: Vesting Commencement Date: Beam Therapeutics Inc. 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement This agreement (this ?Agreement?) evidences an award (this ?Award?) of restricted stock units granted by Beam Therapeutics Inc. (the ?Company?) to the individual named above (the ?Participant?), purs

Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Target

Exhibit 99.1 Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team Bolstered by Appointment of Amy Simon, M.D., as Chief Medical Officer an